Assessment of efficacy and safety of continouation maintenance therapy with gemcitabine after cisplatin-gemcitabine induction chemotherapy in advanced squamous cell lung cancer (KTORG1302) - Assessment of efficacy and safety of CDDP+GEM followed by GEM in advanced squamous cell lung cancer

Kyoto Thoracic Oncology Research Group (KTORG)0 个研究点目标入组 60 人开始时间: 2013年5月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with histologically proven non-squamous cell lung cancer 2) Recognized ILD or pulmonary fibrosis on X-rays 3) Pleural effusion, peritoneal fluid and pericardial fluid that need treatment 4) Superior vena cava syndrome 5) Symptomatic brain metastasis 6) Active concomitant malignancy 7) Prior therapy with gemcitabine 8) Diabetes and hypertension that cannot be controlled 9) Liver cirrhosis 10) Symptomatic or asymptomatic but treated heart disease 11) Severe infectious disease 12) Pregnant women, possibly pregnant women, wishing to become pregnant 13) Serious drug hypersensitivity or a history of drug allergy 14) Refusal of supportive care such as blood transfusion 15) Bleeding tendency 16) Other conditions not suitable for this study

发起方

Kyoto Thoracic Oncology Research Group (KTORG)